Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott–Aldrich syndrome
暂无分享,去创建一个
E. Macintyre | A. Kauskot | A. Toubert | L. Dupré | A. Thrasher | D. Moshous | E. Morris | S. Hacein-Bey-Abina | H. Gaspar | E. Six | C. Booth | M. Miyara | D. Borgel | E. Clave | M. Semeraro | A. Trinquand | G. Gorochov | C. Lagresle | E. Magrin | M. Cavazzana | A. Magnani | A. Gabrion | C. Rivat | C. Picard | R. Elfeky | C. Roudaut | M. Guisset | A. Galy | F. Bushman | J. Bayford | C. Abdo | M. Guiot | A. Denis | F. Suarez | S. Abbas | A. Fischer | A. Roche | F. Adam | R. Petermann | J. Everett
[1] A. Galy,et al. WAS Promoter-Driven Lentiviral Vectors Mimic Closely the Lopsided WASP Expression during Megakaryocytic Differentiation , 2020, Molecular therapy. Methods & clinical development.
[2] L. Notarangelo,et al. Excellent Outcomes Following Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: A PIDTC Report. , 2020, Blood.
[3] F. Bushman,et al. Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs. , 2020, Blood.
[4] C. Pignata,et al. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome , 2019, The Journal of allergy and clinical immunology.
[5] K. Stamatopoulos,et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study , 2019, Leukemia.
[6] L. Biasco,et al. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study , 2019, The Lancet. Haematology.
[7] A. Worth,et al. Bleeding and splenectomy in Wiskott-Aldrich syndrome: A single-centre experience. , 2019, The journal of allergy and clinical immunology. In practice.
[8] W. Ouwehand,et al. A mutation of the human EPHB2 gene leads to a major platelet functional defect. , 2018, Blood.
[9] L. Notarangelo,et al. Autonomous role of Wiskott‐Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation , 2018, The Journal of allergy and clinical immunology.
[10] G. Lucchini,et al. One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years. , 2018, The Journal of allergy and clinical immunology.
[11] S. Kozlovskaya,et al. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ+ and CD19+ Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] Javier Rey-Barroso,et al. The Wiskott-Aldrich Syndrome Protein Contributes to the Assembly of the LFA-1 Nanocluster Belt at the Lytic Synapse. , 2018, Cell reports.
[13] D. Covas,et al. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. , 2018, Blood advances.
[14] F. Bushman,et al. Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. , 2017, Blood.
[15] D. Liggitt,et al. Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector , 2016, Molecular therapy. Methods & clinical development.
[16] Kyle Bittinger,et al. INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions , 2016, Molecular therapy. Methods & clinical development.
[17] Kyle Bittinger,et al. INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes , 2016, Molecular therapy. Methods & clinical development.
[18] E. Meffre,et al. Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. , 2015, The Journal of clinical investigation.
[19] M. van der Burg,et al. B-cell reconstitution after lentiviral vector–mediated gene therapy in patients with Wiskott-Aldrich syndrome , 2015, The Journal of allergy and clinical immunology.
[20] Frederic D Bushman,et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.
[21] Michael Rothe,et al. Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity , 2014, Science Translational Medicine.
[22] Luca Biasco,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.
[23] W. Vainchenker,et al. Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor , 2013, Haematologica.
[24] A. Fischer,et al. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. , 2013, Blood.
[25] Habib Ramezani,et al. A Note on the Normalized Definition of Shannon’s Diversity Index in Landscape Pattern Analysis , 2012 .
[26] H. Ochs,et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. , 2012, Blood.
[27] S. Davies,et al. Outcomes following hematopoietic cell transplantation for Wiskott–Aldrich syndrome , 2012, Bone Marrow Transplantation.
[28] G. Driessen,et al. Paediatric Reference Values for the Peripheral T cell Compartment , 2011, Scandinavian journal of immunology.
[29] A. Fischer,et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. , 2011, Blood.
[30] L. Notarangelo,et al. Clinical spectrum, pathophysiology and treatment of the Wiskott–Aldrich syndrome , 2011, Current opinion in hematology.
[31] M. Bryckaert,et al. Platelet JNK1 is involved in secretion and thrombus formation. , 2010, Blood.
[32] L. Muul,et al. Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. , 2010, Clinical immunology.
[33] S. Burns,et al. WASP: a key immunological multitasker , 2010, Nature Reviews Immunology.
[34] C. Doglioni,et al. Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. , 2010, The Journal of allergy and clinical immunology.
[35] L. Notarangelo,et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. , 2008, Blood.
[36] W. Vainchenker,et al. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. , 2006, Blood.
[37] T. Laín de Lera,et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] Kohsuke Imai,et al. Clinical course of patients with WASP gene mutations. , 2004, Blood.
[39] K. Schwarz,et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. , 2003, Pediatrics.
[40] F. Candotti,et al. Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. , 2003, The Journal of clinical investigation.
[41] F. Adam,et al. Thrombin‐induced platelet PAR4 activation: role of glycoprotein Ib and ADP , 2003, Journal of thrombosis and haemostasis : JTH.
[42] L. Dupré,et al. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. , 2002, Immunity.
[43] H. Ochs,et al. Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. , 2000, Blood.
[44] U. Francke,et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. , 1995, Blood.
[45] V. Kiefel,et al. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. , 1987, Blood.
[46] E. C. Pielou. The measurement of diversity in different types of biological collections , 1966 .
[47] F. Candotti. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome , 2017, Journal of Clinical Immunology.
[48] A. Fischer,et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. , 2008, Blood.
[49] J. Halterman,et al. Neutropenia in pediatric practice. , 2008, Pediatrics in review.
[50] Julia Brasch,et al. Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .